A single-institution, review partner study revealed the rate of opportunistic infections among patients with hematological malignancies who got ibrutinib and distinguished potential patient hazard factors. The study discoveries were published online May 13, 2019, in Leukemia. The records of 566 patients with hematologic malignancies who got ibrutinib between June 2010 and March 2016 were reflectively […]
